Decipher the device reference
This article was originally published in The Gray Sheet
Executive Summary
CDRH Office of Science & Engineering Laboratories Director Larry Kessler stresses the difficulty in substituting premarket requirements with postmarket conditions to speed approval decisions. At a recent Drug Information Association meeting, he recounted: "Recently we had a company approve a really high-profile product, and as one of the conditions of approval of that product, we said we need you to start a registry of new patients so we can see if some of the issues that came up in clinical trials premarket are understood in postmarket, and we're looking forward to it. Several months after the company marketed the product and had sold many, many thousands [of products]...a couple of adverse events showed up that we didn't understand. So we called the company, and we said, 'Hey, we're getting pressure. Clinicians are worried about this. We're worried about this. What have you got on the registry so we can help figure out whether this is a real safety problem?' And you know what they said? 'Registry? Oh, that was a condition of approval. We should have started that. Darn. We've sold thousands of the product, and you know, we haven't registered one person'"...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.